EPRX vs JNJ

Johnson & Johnson (JNJ) offers the better valuation at 38.

4x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Eupraxia Pharmaceuticals Inc. (EPRX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Eupraxia Pharmaceuticals Inc.

(EPRX) delivered a total return of +153. 2%, compared to +46. 1% for Johnson & Johnson (JNJ). Over 10 years, the gap is even starker: EPRX returned +152. 5% versus JNJ's +131. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Eupraxia Pharmaceuticals Inc. 's 1. 36β — meaning EPRX is approximately 2922% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Eupraxia Pharmaceuticals Inc. (EPRX) carries a lower debt/equity ratio of 0% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Eupraxia Pharmaceuticals Inc.

grew EPS -38. 2% year-over-year, compared to -57. 8% for Johnson & Johnson. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus 0. 0% for Eupraxia Pharmaceuticals Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 0. 0% for EPRX. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EPRX: 154.

4% to $19. 00.

In this comparison, JNJ (2.

2% yield) pays a dividend. EPRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Both have compounded well over 10 years (JNJ: +131. 3%, EPRX: +152. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

JNJ pays a dividend while EPRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.